Retrospective Cohort Study
Copyright ©The Author(s) 2024.
World J Gastrointest Surg. May 27, 2024; 16(5): 1291-1300
Published online May 27, 2024. doi: 10.4240/wjgs.v16.i5.1291
Table 1 Comparison of the baseline characteristics of different groups of patients with ampullary adenocarcinoma, n (%)
Characteristic
Total (n = 233)
PNI-low (n = 100)
PNI-high (n = 133)
P value
GenderMale133 (57.1)56 (56.0)77 (57.9)0.772
Female100 (42.9)44 (44.0)56 (41.1)
Age, yr≤ 60141 (60.5)52 (52.0)89 (66.9)0.021
> 6092 (39.5)48 (48.0)44 (33.1)
Tumor size, cm≤ 2112 (48.1)42 (42.0)70 (52.6)0.108
> 2121 (51.0)58 (58.0)63 (47.4)
Tumor differentiationPoor differentiation88 (37.8)43 (43.0)45 (33.8)0.063
Moderate differentiation96 (41.2)43 (43.0)53 (39.8)
Well differentiation49 (21.0)14 (14.0)35 (26.4)
Lymph nodes resection< 17156 (67.0)64 (41.0)92 (59.0)0.406
≥ 1777 (33.0)36 (46.8)41 (53.2)
Vascular invasionNo182 (78.1)74 (74.0)108 (81.2)0.188
Yes51 (21.9)26 (26.0)25 (18.8)
pTT131 (13.3)13 (13.0)18 (13.5)0.8291
T286 (36.9)34 (34.0)52 (39.1)
T3110 (47.2)50 (50.0)60 (45.1)
T46 (2.6)3 (3.0)3 (2.3)
pNN0162 (69.5)64 (64.0)98 (73.7)0.193
N158 (24.9)28 (28.0)30 (22.6)
N213 (5.6)8 (8.0)5 (3.7)
TNM stageI97 (41.6)36 (36.0)61 (45.9)0.213
II65 (27.9)28 (28.0)37 (27.8)
III71 (30.5)36 (36.0)35 (26.3)
Postoperative complicationNo142 (60.9)40 (40.0)51 (38.3)0.798
Yes91 (39.1)60 (60.0)82 (61.6)
Postoperative adjuvant therapyNo152 (65.2)29 (29.0)34 (25.6)0.597
Yes63 (27.0)64 (64.0)88 (74.4)
Unknow18 (7.8)
CA199, U/mL≤ 59.67107 (45.9)38 (38.0)69 (51.9)0.053
> 59.67107 (45.9)52 (52.0)55 (48.1)
Unknow19 (8.2)
ALT, U/L≤ 52.0118 (50.6)47 (47.0)71 (53.4)0.335
> 52.0115 (49.4)53 (53.0)62 (46.6)
AST, U/L≤ 55.0122 (52.4)44 (44.0)78 (58.6)0.027
> 55.0111 (47.6)56 (56.0)55 (41.4)
TBIL, μmol/L≤ 51.3117 (50.2)42 (42.0)75 (56.4)0.030
> 51.3116 (49.8)58 (58.0)58 (43.6)
Cr, μmol/L≤ 62.0115 (49.4)61 (61.0)54 (40.6)0.002
> 62.0118 (50.6)39 (39.0)79 (59.4)
Table 2 Univariate and multivariate analysis of overall survival in patients with ampullary adenocarcinoma
VariateUnivariate analysis
Multivariate analysis
HR
95%CI
P value
HR
95%CI
P value
Gender (male vs female)0.8820.593-1.3130.537
age (≤ 60 vs > 60)1.1470.769-1.7130.501
Tumor size (≤ 2 vs > 2)1.1420.773-1.6890.504
Tumor differentiation (non-well vs well)0.6670.407-1.0940.109
Lymph nodes resection (< 17 vs ≥ 17)1.1610.761-1.7710.488
Vascular invasion (No vs Yes)1.3180.846-2.0530.222
pT (T1, T2 vs T3, T4)2.1141.417-3.153< 0.0011.9011.257-2.8760.002
pN (N0 vs N1, N2)2.1971.454-3.319< 0.0011.8511.209-2.8340.005
Postoperative complication (No vs Yes)1.0430.695-1.5670.838
Postoperative adjuvant therapy (No vs Yes)1.4320.934-2.1950.100
PNI (< 45.3 vs ≥ 45.3)0.5840.393-0.8660.0070.5690.383-0.8460.005
Table 3 Univariate and multivariate analysis of disease-free survival in patients with ampullary adenocarcinoma
VariateUnivariate analysis
Multivariate analysis
HR
95%CI
P value
HR
95%CI
P value
Gender (male vs female)0.9450.653-1.3670.764
Age (≤ 60 vs > 60)1.0480.723-1.5180.806
Tumor size (≤ 2 vs > 2)1.2130.844-1.7450.297
Tumor differentiation (non-well vs well)0.6660.420-1.0560.084
Lymph nodes resection (< 17 vs ≥ 17)1.0610.711-1.5830.771
Vascular invasion (No vs Yes)1.5231.012-2.2910.0441.0630.677-1.6680.792
pT (T1, T2 vs T3, T4)1.9751.363-2.861< 0.0011.8191.215-2.7230.004
pN (N0 vs N1, N2)2.1131.440-3.101< 0.0011.7931.130-2.8460.013
Postoperative complication (No vs Yes)1.0220.701-1.4910.909
Postoperative adjuvant therapy (No vs Yes)1.5911.072-2.3600.0210.9580.590-1.5570.863
PNI (< 45.3 vs ≥ 45.3)0.6310.438-0.9090.0130.6740.464-0.9800.039